Sanctuary Advisors LLC purchased a new position in shares of Emergent Biosolutions Inc. (NYSE:EBS – Free Report) during the second quarter, HoldingsChannel reports. The firm purchased 89,117 shares of the biopharmaceutical company’s stock, valued at approximately $747,000.
Several other institutional investors and hedge funds have also added to or reduced their stakes in EBS. CWM LLC grew its stake in Emergent Biosolutions by 5.5% in the fourth quarter. CWM LLC now owns 18,009 shares of the biopharmaceutical company’s stock valued at $223,000 after acquiring an additional 942 shares during the period. Franklin Resources Inc. raised its position in shares of Emergent Biosolutions by 2.3% during the fourth quarter. Franklin Resources Inc. now owns 78,945 shares of the biopharmaceutical company’s stock worth $976,000 after purchasing an additional 1,764 shares during the period. SG Americas Securities LLC raised its position in shares of Emergent Biosolutions by 4.6% during the first quarter. SG Americas Securities LLC now owns 42,394 shares of the biopharmaceutical company’s stock worth $352,000 after purchasing an additional 1,865 shares during the period. Deutsche Bank AG lifted its holdings in shares of Emergent Biosolutions by 1.1% in the 4th quarter. Deutsche Bank AG now owns 181,744 shares of the biopharmaceutical company’s stock worth $2,246,000 after purchasing an additional 1,941 shares in the last quarter. Finally, Values First Advisors Inc. lifted its holdings in shares of Emergent Biosolutions by 0.9% in the 1st quarter. Values First Advisors Inc. now owns 307,880 shares of the biopharmaceutical company’s stock worth $2,555,000 after purchasing an additional 2,834 shares in the last quarter. Institutional investors own 78.40% of the company’s stock.
Insider Transactions at Emergent Biosolutions
In other news, SVP Paul Anthony Williams sold 3,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total value of $25,200.00. Following the completion of the sale, the senior vice president owned 159,098 shares in the company, valued at $1,336,423.20. This represents a 1.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
Get Our Latest Analysis on EBS
Emergent Biosolutions Stock Down 0.3%
EBS stock opened at $5.92 on Friday. The firm has a market capitalization of $303.52 million, a PE ratio of -1.67 and a beta of 2.35. The company has a quick ratio of 2.95, a current ratio of 5.42 and a debt-to-equity ratio of 1.70. Emergent Biosolutions Inc. has a twelve month low of $4.36 and a twelve month high of $14.06. The stock’s 50 day moving average is $6.88 and its 200-day moving average is $8.08.
Emergent Biosolutions (NYSE:EBS – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.68. The business had revenue of $234.30 million during the quarter, compared to the consensus estimate of $177.50 million. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%. Sell-side analysts expect that Emergent Biosolutions Inc. will post -4.61 EPS for the current fiscal year.
Emergent Biosolutions Company Profile
Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.
Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.
Read More
- Five stocks we like better than Emergent Biosolutions
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc. (NYSE:EBS – Free Report).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.
